Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Made immune protein takes on advanced cancers in first human test

NCT ID NCT02009449

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot under the skin, either alone or together with standard chemotherapy. The main goals are to check the drug's safety, find the best dose, and see if it helps control tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pegilodecakin (a lab-made immune protein called PEGylated interleukin-10)
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early, first-in-human trial focused on safety and dosing, so it is not yet known if pegilodecakin effectively shrinks tumors or improves survival. Side effects from the drug or chemotherapy combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm castration-resistant prostate carcinoma colorectal carcinoma colorectal neoplasm exocrine pancreatic carcinoma melanoma neoplasm non-small cell lung carcinoma ovarian cancer pancreatic adenocarcinoma pancreatic neoplasm prostate cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLORECTAL CARCINOMA MELANOMA NON SMALL CELL LUNG CARCINOMA OVARIAN CANCER PANCREATIC CARCINOMA PROSTATE CANCER RENAL CELL CARCINOMA SOLID TUMORS

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Florida Cancer Specialists & Research Institute

    Sarasota, Florida, 34232, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado, 80218, United States

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas, 78229, United States

  • Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program

    Oklahoma City, Oklahoma, 73104, United States

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UCLA Medical Hematology & Oncology

    Los Angeles, California, 90024, United States

  • UCSF

    San Francisco, California, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.